生物制药公司Trevi Therapeutics（TRVI）周四盘后股价大涨5%，主要受益于公司发布的第一季度财报好于市场预期。
根据公司公布的财报，截至3月31日的第一季度，Trevi Therapeutics调整后每股亏损9美分，优于分析师平均预期的12美分亏损。这一业绩也好于去年同期的11美分亏损。尽管公司报告的季度亏损总额为1,034万美元，但较低的每股亏损显示公司在成本控制方面取得了进展。
值得注意的是，Trevi Therapeutics股价表现强劲，本季度已上涨5.9%，今年迄今为止更是大涨61.7%。分析师对公司前景保持乐观，目前对该股的平均评级为"买入"，12个月目标价中位数为20.00美元。这些因素共同推动了投资者的信心，促使股价在盘后交易中大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.